Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
38 hedge funds and large institutions have $18.1M invested in Baudax Bio, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 24 closing their positions.
1,041% more call options, than puts
Call options by funds: $4.14M | Put options by funds: $363K
7% more capital invested
Capital invested by funds: $16.9M → $18.1M (+$1.19M)
19% less funds holding
Funds holding: 47 → 38 (-9)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
69% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$907K |
| 2 |
Millennium Management
New York
|
+$787K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$561K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$235K |
| 5 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$221K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.51M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.37M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.28M |
| 4 |
BlackRock
New York
|
-$1.14M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.07M |
BXRX Hedge Fund Activity: Q2 2020 in Review
38 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2020, worth a combined $18.1M — up 7.1% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BXRX and 15 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 5 added.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $907K. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $1.51M sold.
- 38 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2020, down from 47 in Q1 2020.
- Funds reported $18.1M of Baudax Bio, Inc. Common Stock stock for Q2 2020, up 7.1% quarter-over-quarter.
- 15 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2020 and 24 closed out, a net change of -9 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q2 2020 was Arrowstreet Capital, an estimated $907K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q2 2020 was Stonepine Capital Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q2 2020.